Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF)... | NCT07743996

NCT07743996

Overview

NCT ID: NCT07743996
Lead Sponsor: Boehringer IngelheimINDUSTRY
Official Title: A Real-World Study of the Perceived Emotional and Social Experiences Related to Antifibrotic Therapy in Patients With IPF and PPF: A Cross-Sectional Web-Based Survey
Brief Summary: This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire.

This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.
Conditions: Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks

Patients capable of responding to a self-administered questionnaire

Exclusion Criteria:

Patients treated with nerandomilast (including clinical trials)

Patients with PPF treated with pirfenidone

Patients currently hospitalized

Patients with malignant tumors

Central Contacts: Boehringer IngelheimContact
clintriage.rdg@boehringer-ingelheim.com

NCT07722507Not yet recruiting

Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

NCT02803580Completed

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

NCT03104322Completed

Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis

NCT05875532Completed

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

NCT03744598Terminated

Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis

NCT06485635Completed

Real-life-persistence to Antifibrotic Treatments

NCT04148157Completed

Quality of Life in IPF - Patient and Physician Perceptions

NCT06629623Enrolling by invitation

Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis